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Background: Individual behavior in the face of the COVID-19 
pandemic is characterized by disruptions or shifts in lifestyle. 
Covid-19 is more likely to cause extreme symptoms or serious 
problems in people with some medical conditions (chronic 
noncommunicable diseases). Hypertension is a non-
communicable chronic condition induced by an unhealthy 
lifestyle. According to data from the national covid-19 
distribution map, hypertension is the comorbid condition with 
the highest number of covid-19 patients. 
Methods: This study uses a descriptive analysis with a non-
experimental framework as its process (cross-sectional). 
According to the study's goals, research participants used 
secondary data from the Covid-19 Indonesia distribution map 
in 2020/2021. 
Results: The number of confirmed cases is about 10,000 
residents in July 2020, and it will continue to rise until May 
2021, when it will reach 1,400,000 cases. Hypertension, which 
accounts for 50.1 percent of covid-19 cases, is one of the most 
common comorbidities. Diabetes mellitus affects 36.6 percent 
of people, the heart 17.2 percent, and 10 percent of pregnant 
women. Lung and kidney disease affect about 5% of people, 
other respiratory diseases affect 2.2 percent, and cancer, 
immune disorders, asthma, liver, and tuberculosis affect less 
than 2% of people. 
Conclusion: Patients with hypertension should be mindful of 
the risk of contracting Covid-19. Because of the extent of the 
losses incurred by the Covid-19 pandemic, different parties 
must work together to avoid and manage it. 
 
Keywords: Management, Risk, Hypertension, Covid-19 
 
INTRODUCTION 
Covid-19 is a disorder that affects people of all ages 
and genders. Covid-19, but in the other hand, is considered to 
be more likely to attack people who have such medical 
conditions. Covid-19 is more likely to cause complications and 
more serious symptoms in this population. Shortness of 
breath, chest pain, and a high fever are not always serious 
Covid-19 symptoms in people infected with the Corona virus. 
Any people who are infected with Covid-19 only have mild flu-
like symptoms. Even if they have been positively infected with 
Covid-19, some people experience no symptoms at all. 
According to WHO and the Ministry of Health of the Republic 
of Indonesia, the elderly and people with some medical 
conditions, such as people with chronic noncommunicable 
diseases, are more likely to experience extreme symptoms 
and serious complications as a result of Covid-19 (1) 
Covid-19 cases are widespread across the world, 
and the pandemic has lasted more than a year. According to 
WHO data as of May 12, 2021, there were 158,651,638 
confirmed positive cases worldwide, with 3,299,764 cases 
dying. In Southeast Asia, a total of 26,660,141 cases were 
reported positive, with 322,390 deaths. There were 1,723,596 
reported positive cases in Indonesia, with 47,465 deaths. Out 
of the ten member countries in Southeast Asia, Indonesia has 
the second highest case (2) 
Covid-19 was first discovered in Indonesia on March 
2, 2020. During the COVID-19 pandemic, people with 
comorbidities are one of the groups most at risk of contracting 
the virus (3). Hypertension, diabetes, and heart disease are 
indeed a several of the comorbidities. (4) (5). As a result, the 
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government, through the Ministry of Health, is paying close 
attention because if COVID-19 is confirmed, the person's 
clinical condition may deteriorate, raising the risk of death (6). 
Hypertension is the most common form of comorbid disease 
in Indonesia, out of the 12 that were studied (7). Hypertension 
continues to be an issue in both developed and developing 
countries. The high prevalence of hypertension in Indonesia 
may be recognized. Myocardial infarction, also known as the 
silent killer, is the most prevalent consequence of 
hypertension in Indonesia. Continuous therapy is required in 
the treatment of hypertension.  Where it may be deduced that 
the patient must continue to take their medicines on a regular 
basis in order to avoid further difficulties (8). Non-
Communicable Diseases (NCDs) are generally chronic in 
nature, lowering the immune system of the sufferer over time 
and making them vulnerable to infections, including those 
caused by the COVID-19 virus (9). One of the most common 
comorbidities in Coronavirus disease-19 (COVID-19) is 
hypertension, which is linked to a poor prognosis for the 
infection (10). To help reduce the risk of complications from 
hypertension, risk management is required. 
The aim of this study is to classify cases of hypertension 
in confirmed Covid-19 patients and to implement risk 
management for the population at risk of infection. The 
findings are likely to be one of the factors considered by 
stakeholders when making decisions on how to reduce the risk 
of transmission in population groups with comorbidities. 
 
METHODS 
According to the study objectives, research subjects used 
secondary data from data WHO, WHO SEAR, dan Data Covid 
19 Nasional period of Time since end of March 2020 – May 
2021 (Covid19.go.id). In this research, secondary data for 
Covid-19 will be displayed. This analysis of this study is non-
experimental and is a descriptive analytic study (cross 
sectional).  In terms of case numbers and those with comorbid 
diseases, the study's population included everybody in the 
world, Southeast Asia, and Indonesia, as well as those with 













 Data on Covid-19 in Indonesia was obtained based on the 
research findings. As of May 2021, the following data on the 
total number of cases will be shown in Figure 1.   
Figure 1 shows that the number of Covid-19 cases is steadily 
rising month after month. In July 2020, the number of cases 
seemed to have risen, but it was still below the 100,000-case 
threshold. The number of cases continues to rise until May 
2021, when it will surpass 1,400,000 nationwide.  
Figure 2 shows the number of Covid-19 cases depending on 
comorbid conditions. Hypertension is the comorbid condition 
with the largest number of sufferers from other forms of 
comorbidities, as seen in Figure 2. Hypertension (50.1%), 
Diabetes mellitus (36.6%), Heart (17.2%), Pregnancy (10%), 
Lung and Kidney Disease (5.2%), Other Respiratory Diseases 
(2.2%), Cancer, Immune Disorders, Asthma, Liver, and 
Tuberculosis (TB) (less than 2%), Cancer,  















































Figure 1, there is a significant expectation of Covid-19 case  ta in Indonesia 




















Figure 2. Comorbid condition Covid-19 Positive 
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DISCUSSION 
Coronavirus disease-19 (COVID-19) has been declared 
a global pandemic by the World Health Organization (WHO) 
because it has become viral and is increasingly spreading 
across the world. The majority of cases that result in death are 
due to comorbidities. Coronavirus disease-19 (COVID-19) 
patients are more likely to die if they have hypertension, which 
is one of the most common comorbidities. While hypertension 
cannot be cured, it can be managed with medication (11) 
Uncontrollable risk factors for hypertension include 
gender, age, and genetics, while controllable risk factors 
include a balanced lifestyle that includes a high-fat, high-
cholesterol diet, excessive salt consumption, smoking habits, 
consuming alcohol, a lack of exercise, being overweight, and 
being depressed. The age factor has an effect on blood 
pressure rise (12) 
 
A. Risk assessment depending on the dimensions that 
must be assessed 
1. The frequency at which losses occur 
a. National Loss 
The aggregate losses around the country 
are the easiest to quantify. Since this 
measure is macro in nature, it is only used 
by large-scale economic players or the 
government when planning (revising) the 
APBN. One method is to use the 
reference Gross Domestic Product 
(GDP), which is a year's worth of total 
output in a country. According to the 
Central Statistics Agency (BPS), 
Indonesia's annual per capita Gross 
Domestic Product (GDP) is USD 4,174.9 
or IDR 59.1 million in 2019. (exchange 
rate IDR 14,156 per USD). Indonesia's 
GDP in 2019 will be IDR 15,833.9 trillion, 
with a population of 267 million. (13)  
2. Economic Loss 
Layoffs, the occurrence of PMI 
Manufacturing Indonesia, decreased 
imports, increased prices (inflation), and 
losses in the tourism sector resulted in a 
decline in occupancy have all had an 
effect on the Indonesian economy as a 
result of the pandemic (14). The real effect 
of Covid on the economy that can be seen 
right now is the occurrence of layoffs. 
Many workers have been fired, and 
several businesses have been threatened 
with bankruptcy. A total of 114,340 
businesses have laid off or laid off 
employees, affecting a total of 1,943,916 
workers, with the formal sector accounting 
for 77% of the total and the informal sector 
accounting for 23%. (15) 
3. Sectoral Loss 
The state budget would be impacted by 
national economic declines. And on April 
1, 2020, the Minister of Finance, Sri 
Mulyani, made corrections (16) . However, 
the aggregate statistic cannot always be 
used by business actors. This is due to the 
fact that not all businesses suffer the 
same losses. Certain industries, in 
particular, profit from social constraints. 
As a result, calculations must be made 
based on the business sector, followed by 
individual company calculations 
(corporation) (13) 
4. Individual Loss and Corporate 
(Bussiness People) 
Individuals and businesses are 
collectively responsible for the execution 
of all of the above loss estimates. 
Countries suffer 'losses' as revenue falls - 
mostly due to taxes - as spending rises 
due to the need to cope with crises, 
provide social safety nets, and care for 
sick people, deploying more medical and 
personnel, paying interest on new loans, 
and so on. However, the losses will be 
offset by future (tax and non-tax) revenue, 
ensuring that the state will break even or 
make a profit, unless there is leakage, 
bribery, or corruption of state assets 
during implementation. (13) 
5. Other Potential Downside 
Aside from the losses that can be 
measured above, non-business causes 
can also cause losses. For instance, if 
economic hardships have resulted in a 
rise in crime and the destruction of 
commercial properties. As is well known, 
over 30 thousand inmates have been 
released due to fears of Covid-19 
spreading in overcrowded jails. (13) 
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2. The Severity or Severity of The Loss 
Comorbidities have significant indications for 
the disease outcome of COVID-19 (17). One of the 
most common comorbidities in COVID-19 patients is 
hypertension. In COVID-19 patients with ARDS, 
hypertension is also normal. Although it is uncertain 
if uncontrolled hypertension is a risk factor for 
contracting COVID-19, blood pressure monitoring is 
still recommended to minimize disease burden. (18) 
Patients with comorbidities such as 
cardiovascular disease, diabetes, asthma, chronic 
respiratory disease, and malignancy have a higher 
mortality rate in severe cases (19). Specific 
comorbidities have been linked to an increased risk 
of infection and worse outcomes, including the 
development of increased severity of lung injury and 
mortality, according to research from Johns Hopkins 
University. According to one study, the most 
common comorbidities were hypertension (30%), 
diabetes (19%), and coronary heart disease (8 
percent) (20). Corona patients with congenital 
disorders like diabetes and hypertension, as well as 
patients with weakened immunity, have higher care 
costs for corona or Covid-19. Treatment cost an 
average of Rp. 184 million, ranging from Rp. 2.4 
million to Rp. 446 million. The government has set 
aside IDR 695.2 trillion for dealing with the covid-19 
pandemic. The health budget was allocated Rp. 
87.55 trillion out of this total. The high costs of 
treating corona or covid-19 patients are followed by 
fear of corona's worst side effects during treatment 
(21) 
 
B. Handling Covid-19 in the Presence of Hypertension: 
Risk Management 
Non-Communicable Diseases (NCDs) are usually 
chronic in nature, lowering the immune system of the 
sufferer over time and making them vulnerable to infection, 
including infections caused by the COVID 19 virus. PTM 
patients are a COVID 19 fragile and comorbid category. 
Hypertension is a condition that is directly linked to one's 
actions and lifestyle, so it can be treated by altering one's 
behavior to lead a healthier life (9). 
Here are several attempts to reduce the risk of 
Covid-19 transmission in hypertension patients: 
1. Health and clean life style 
Regularly monitoring blood pressure, keeping 
food safe by reducing sugar, salt, and fat intake, 
avoiding sweet foods, consuming more fruits 
and vegetables, maintaining an ideal body 
weight, and engaging in regular physical activity 
such as cycling or performing everyday activities 
at home are all ways to start living a clean and 
healthy lifestyle. 
2. Early detection 
For people who have risk factors, early detection 
in the form of measuring blood pressure can be 
performed once a month, while stable people will 
have to scan at least once in a span of 6 months 
to 1 year. 
3. Medication and screening 
This is followed up by a referral to a First Level 
Health Service Facility (FKTP) so that 
hypertension can be avoided and monitored 
right away. The main keys to identifying cases 
as early as possible so that effective procedures 
can be carried out are screening and early 
identification of accurate and normal blood 
pressure measurements. 
4. Discipline in carrying out 3M movement 
To prevent transmission of Covid-19 from one 
person to another, everyone must wear a mask, 
keep a safe distance, and wash their hands. 
Good people without comorbidities and people 
with comorbidities must work together to protect 
themselves and the world in order to stop the 
pandemic from spreading. 
5. Health promotion 
One way to reduce the prevalence of 
hypertension is to provide public health 
education. (7). To increase awareness and 
encourage the public to suppress the chain of 
spread of the Corona Virus, health education 
related to prevention and control of the spread 
of COVID-19 is required. (22) 
 
Because of the large number of covid-19 cases of 
hypertension as a comorbid condition, sufferers of 
hypertension should be conscious of the risk of covid-19 
transmission. Because of the extent of the losses incurred by 
the Covid-19 pandemic, different parties must work together 
to avoid, manage, and monitor it. Both parties must make 
efforts to live a safe life and take steps to avoid the spread of 
covid-19. 
This study will include an initial summary of the risks 
and risk management for dealing with Covid-19, with 
hypertension being one of the factors that makes an individual 
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more susceptible to Covid-19. Covid-19 patients with 
hypertension are predicted to be identified through further 
studies. or other unique comorbidities dependent on the area 
or demographic factors of each province in Indonesia, so that 
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